Trials / Active Not Recruiting
Active Not RecruitingNCT05559359
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy, Safety and Pharmacokinetics of Lebrikizumab Compared to Placebo in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 367 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 6 Months – 17 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lebrikizumab | Administered SC |
| DRUG | Placebo | Placebo given SC |
| DRUG | Topical Corticosteroid (TCS) | TCS administered |
Timeline
- Start date
- 2022-10-18
- Primary completion
- 2026-01-14
- Completion
- 2026-12-01
- First posted
- 2022-09-29
- Last updated
- 2026-01-21
Locations
85 sites across 12 countries: United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Japan, Mexico, Poland, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05559359. Inclusion in this directory is not an endorsement.